Tel. +39 010.51862.1

Our history since 1915

Projecting the present into the future

PIAM, the first company on the Italian market to work in the field of hereditary metabolic diseases, has introduced innovative and technologically advanced products, devoting itself to the development of increasingly effective, practical and highly palatable formulas with a view to improve treatment compliance.

PIAM works alongside Kyowa Hakko Bio, a world leader in biotechnology and chemical synthesis, with lines of amino acids, vitamins, nucleic acids and compounds for pharmaceutical and nutritional treatments.
PIAM is a long-standing partner of Vitaflo, a company that is specialized in human nutrition for the treatment of hereditary metabolic diseases and is part of the Nestlé Health Science group.

PIAM acts as a one-stop reference point on the market, with skills in the pharmaceutical and medical food areas, offering twofold expertise with a high degree of specialisation and diverse therapeutic treatments, customised for the management of rare and niche disorders.
PIAM’s commitment never stops and it focuses on investing in research and innovation in the orphan drugs sector, a strategic market that still requires a great deal of hard work because many rare diseases are lacking in accessible and adequate treatments.
PIAM continues to work alongside the scientific community and patients, constantly seeking out the best therapeutic solutions to protect the health of all patients.

1915

PIAM (Prodotti Igienici Alimentari Medicinali)
is founded in Genoa

1950-1960

Nicozid and Etapiam are launched on the market. PIAM establishes itself as market leader in the treatment of tuberculosis

1980

PIAM is the first pharmaceutical company to import medical food in Italy for treating hereditary metabolic diseases

2014

Change of ownership.
New shareholders and majority stake, new management and a new strategic drive

100 years by your side

Founded in Genoa in 1915 by Edoardo Maragliano, the man who discovered the first tuberculosis vaccine, PIAM is an Italian pharmaceutical company that has developed its core business in specialist and ethically significant therapeutic areas with prescription drugs.

Over time it has gained particular expertise in hereditary metabolic diseases. In the 70s, PIAM pioneered a specialist nutritional line to support its pharmaceutical products. It is able to offer a complete response for patients with disorders requiring particular nutritional therapy, throughout every phase of their lives.

1915

PIAM (Prodotti Igienici Alimentari Medicinali) is founded in Genoa

1950-1960

Nicozid and Etapiam are launched on the market. PIAM establishes itself as market leader in the treatment of tuberculosis

1980

PIAM is the first pharmaceutical company to import medical food in Italy for treating hereditary metabolic diseases

2014

Change of ownership.
New shareholders and majority stake, new management and a new strategic drive

100 years by your side

Founded in Genoa in 1915 by Edoardo Maragliano, the man who discovered the first tuberculosis vaccine, PIAM is an Italian pharmaceutical company that has developed its core business in specialist and ethically significant therapeutic areas with prescription drugs.

Over time it has gained particular expertise in hereditary metabolic diseases. In the 70s, PIAM pioneered a specialist nutritional line to support its pharmaceutical products. It is able to offer a complete response for patients with disorders requiring particular nutritional therapy, throughout every phase of their lives.

Our Figures

28,978

Turnover (2017 forecast),
10% CAGR (Compound Average Growth Rate)
2014-2017

15

CMO
(Contract Manufactor Organization)
including 5 international CMOs

100%

Presence
in Italian Hospital
Metabolic Centres

70

Partnerships with
Parkinson’s disease
treatment Centres

15

Projects underway
with Scientific
and Patient Associations